ResearcherRadboud University Medical CenterActive in the last 2 years
E. Smeets
Matched on ORCID iD 0000-0002-8350-2131; OpenAlex author ID A5004148771. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 35
2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers
Papers 7
- Automatic quantification of tumor-stroma ratio as a prognostic marker for pancreatic cancer. Co-author DOI 10.1371/journal.pone.0301969↗
- Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer. Co-author DOI 10.2967/jnumed.123.266262↗
- Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma. First author DOI 10.1021/acs.molpharmaceut.3c00453↗
- Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. Co-author DOI 10.1038/s41467-021-27088-9↗
- Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s40170-022-00298-5↗
- Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2021.07.23.452145↗
- Optimal respiratory-gated [18F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their correlation with overall survival in patie… Co-author DOI 10.1186/s13550-019-0492-y↗
Closest collaborators
The 25 strongest of 35 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Erik H.J.G. Aarntzen · 6 shared papers, 2019–2024 · strength 0.76
- Paper Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer. DOI 10.2967/jnumed.123.266262↗
- Paper Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancr… DOI 10.1021/acs.molpharmaceut.3c00453↗
- Paper Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. DOI 10.1186/s40170-022-00298-5↗
- Jens Thomas Siveke · 5 shared papers, 2021–2024 · strength 0.66
- Paper Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer. DOI 10.2967/jnumed.123.266262↗
- Paper Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancr… DOI 10.1021/acs.molpharmaceut.3c00453↗
- Paper Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. DOI 10.1186/s40170-022-00298-5↗
- Marija Trajkovic‐Arsic · 4 shared papers, 2021–2024 · strength 0.56
- Paper Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer. DOI 10.2967/jnumed.123.266262↗
- Paper Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancr… DOI 10.1021/acs.molpharmaceut.3c00453↗
- Paper Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. DOI 10.1186/s40170-022-00298-5↗
- Phyllis F. Cheung · 4 shared papers, 2021–2023 · strength 0.46
- Paper Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancr… DOI 10.1021/acs.molpharmaceut.3c00453↗
- Paper Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. DOI 10.1186/s40170-022-00298-5↗
- Paper Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. DOI 10.1038/s41467-021-27088-9↗
- Martin Gotthardt · 3 shared papers, 2019–2024 · strength 0.46
- Paper Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer. DOI 10.2967/jnumed.123.266262↗
- Paper Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancr… DOI 10.1021/acs.molpharmaceut.3c00453↗
- Paper Optimal respiratory-gated [18F]FDG PET/CT significantly impacts the quantification of metabolic parameters and their co… DOI 10.1186/s13550-019-0492-y↗
- Lodewijk A.A. Brosens · 2 shared papers, 2024 · strength 0.44
- Rickmer Braren · 3 shared papers, 2021–2024 · strength 0.39
- Paper Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer. DOI 10.2967/jnumed.123.266262↗
- Paper Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. DOI 10.1186/s40170-022-00298-5↗
- Paper Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma DOI 10.1101/2021.07.23.452145↗
- Smiths Lueong · 3 shared papers, 2021–2022 · strength 0.30
- Paper Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma. DOI 10.1186/s40170-022-00298-5↗
- Paper Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression. DOI 10.1038/s41467-021-27088-9↗
- Paper Functional metabolic phenotyping of human pancreatic ductal adenocarcinoma DOI 10.1101/2021.07.23.452145↗
- Pierpaolo Vendittelli · 1 shared paper, 2024 · strength 0.24
- Valentyna Kryklyva · 1 shared paper, 2024 · strength 0.24
- Geert J. S. Litjens · 1 shared paper, 2024 · strength 0.24
- Caroline Sophie Verbeke · 1 shared paper, 2024 · strength 0.24
- Andrea Tannapfel · 2 shared papers, 2021–2022 · strength 0.20
- Waldemar H. Uhl · 2 shared papers, 2021–2022 · strength 0.20
- Irina Heid · 2 shared papers, 2021–2022 · strength 0.20
- Stephan A. Hahn · 2 shared papers, 2021–2022 · strength 0.20
- Laura Godfrey · 2 shared papers, 2021–2022 · strength 0.20
- Jörg D. Hoheisel · 2 shared papers, 2021–2022 · strength 0.20
- Christian Klein · 1 shared paper, 2023 · strength 0.17
- Sanne A. M. van Lith · 1 shared paper, 2023 · strength 0.17
- Daphne N. Dorst · 1 shared paper, 2023 · strength 0.17
- Martijn W.J. Stommel · 1 shared paper, 2023 · strength 0.17
- Wilko Weichert · 1 shared paper, 2022 · strength 0.11
- John J. Hermans · 1 shared paper, 2019 · strength 0.10
- Cees J. H. M. van Laarhoven · 1 shared paper, 2019 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.